Transgenic mouse models of Alzheimer's disease (AD) show some characteristic features of the disease, and we aim to further bridge the gap between studies of humans with AD, those at risk, and these murine models by providing shared markers of disease which could be used to track progression and assess future interventions. Brain imaging measurements may prove useful in this regard. We previously found that the homozygous PDAPP mouse model of AD showed significant declines in glucose uptake with age in posterior cingulate cortex (PCC), an area homologous to the human posterior cingulate, which shows significant declines in AD and in those at risk for AD. To further evaluate this potential biomarker and its correlation across age, we used fluorodeoxyglucose (FDG) autoradiography at two ages (2 and 12 months) in wildtype, heterozygous, and homozygous PDAPP mice. We found significant posterior cingulate fluorodeoxyglucose uptake declines again in homozygous PDAPP mice, but at both ages assessed. There was a strong effect of gene dose; homozygous mice showed larger and earlier effects. These results, in conjunction with our previous analyses, indicate a nonlinear progression stemming from synergistic effects of the overexpressed mutant gene, both developmental and pathological. The posterior cingulate is preferentially vulnerable to both effects of transgene in the PDAPP mouse, and both are independent of amyloid deposition.
Fluorodeoxyglucose (FDG) positron emission tomography (PET) studies find that persons with Alzheimer's disease (AD) characteristically show preferential and progressive neocortical reductions in measurements of the cerebral metabolic rate for glucose or FDG uptake, with the largest reduction found in the posterior cingulate cortex (PCC; Minoshima et al., 1994 Minoshima et al., , 1997 Reiman et al., 1996) . We have also examined the postmortem PCC and showed that the glucose uptake abnormalities may be related to decrements in mitochondrial oxidative energy metabolism in AD (Valla et al., 2001) . Parallel to imaging studies in humans, we have mapped metabolic activity in the brains of transgenic mouse models of AD with the hope of providing a new surrogate marker of AD processes which could be used to help clarify disease mechanisms and screen candidate treatments. We previously reported (Reiman et al., 2000) a highly significant, preferential and progressive (i.e., found in 18-month-old but not 4-month-old mice) reduction in FDG uptake in the PCC of homozygous transgenic mice overexpressing human mutant b-amyloid precursor protein (PDAPP; Games et al., 1995) . The finding in this region was enticing as the rodent PCC is generally homologous to the human, subserving similar functions, such as spatial (Vann et al., 2000) and associative/discriminative (Gabriel et al., 1987) learning.
We performed this study to further establish the time course of regional functional effects in the PDAPP mouse brain. Secondarily, we sought to assess not only homozygous mice as before, but also the more widely distributed and utilized heterozygous mice, for comparable effects despite their lower gene dose and expression level.
